NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis $3.05 +0.22 (+7.77%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About X4 Pharmaceuticals Stock (NASDAQ:XFOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get X4 Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.77▼$3.0550-Day Range$2.45▼$3.6252-Week Range$2.43▼$4.83Volume662,921 shsAverage Volume648,473 shsMarket Capitalization$302.41 millionP/E RatioN/ADividend YieldN/APrice Target$11.25Consensus RatingModerate Buy Company Overview X4 Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body. Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections. X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia. The company’s work has centered on therapies that target CXCR4 to help improve immune-cell circulation.AI Generated. May Contain Errors. Read More X4 Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreXFOR MarketRank™: 1.672850139125 of 5 starsX4 Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 719th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingX4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialX4 Pharmaceuticals has a consensus price target of $11.25, representing about 279.4% upside from its current price of $2.97.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about X4 Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for X4 Pharmaceuticals are expected to decrease in the coming year, from ($0.67) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.13% of the float of X4 Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 10.86, which indicates bearish sentiment.Change versus previous monthShort interest in X4 Pharmaceuticals has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.41 News SentimentX4 Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have sold 183.57% more of their company's stock than they have bought. Specifically, they have bought $11,868.00 in company stock and sold $33,654.00 in company stock.Percentage Held by Insiders1.13% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about X4 Pharmaceuticals' insider trading history. Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XFOR Stock News HeadlinesBrookline Capital Markets Comments on XFOR FY2030 EarningsNovember 9, 2026 | americanbankingnews.comX4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 17 at 1:00 AM | Behind the Markets (Ad)X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 4, 2026 | globenewswire.comX4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026November 3, 2026 | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day TranscriptOctober 30, 2026 | seekingalpha.comX4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor DayOctober 29, 2026 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) Chairman Purchases 4,600 Shares of StockOctober 20, 2026 | insidertrades.comSee More Headlines XFOR Stock Analysis - Frequently Asked Questions How have XFOR shares performed this year? X4 Pharmaceuticals' stock was trading at $4.00 at the beginning of the year. Since then, XFOR stock has decreased by 25.9% and is now trading at $2.9650. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced its earnings results on Thursday, November, 5th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.01. The business had revenue of $2.88 million for the quarter, compared to analysts' expectations of $2.78 million. X4 Pharmaceuticals had a negative trailing twelve-month return on equity of 49.62% and a negative net margin of 474.74%. When did X4 Pharmaceuticals' stock split? X4 Pharmaceuticals shares reverse split on the morning of Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did X4 Pharmaceuticals IPO? X4 Pharmaceuticals (XFOR) raised $40 million in an initial public offering (IPO) on Thursday, November 16th 2017. The company issued 4,000,000 shares at a price of $10.00 per share. Who are X4 Pharmaceuticals' major shareholders? Top institutional investors of X4 Pharmaceuticals include Goldman Sachs Group Inc. (2.36%), State Street Corp (1.74%), Integral Health Asset Management LLC (0.25%) and Russell Investments Group Ltd. (0.22%). Insiders that own company stock include Adam R Craig, John Volpone, David Kirske, Paula Ragan, Mark Baldry, Mary Dibiase, Arthur Taveras and Adam S Mostafa. View institutional ownership trends. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Viking Therapeutics (VKTX), NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Pfizer (PFE), Sorrento Therapeutics (SRNE) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/05/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 XFOR's financial health is in the Green zone, according to TradeSmith. XFOR has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XFOR CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees45Year Founded2010Price Target and Rating Average Price Target for X4 Pharmaceuticals$11.25 High Price Target$12.00 Low Price Target$10.00 Potential Upside/Downside+268.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.20 million Net Margins-474.74% Pretax Margin-474.71% Return on Equity-49.62% Return on Assets-30.80% Debt Debt-to-Equity Ratio0.55 Current Ratio13.22 Quick Ratio12.86 Sales & Book Value Annual Sales$35.11 million Price / Sales8.61 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book2.18Miscellaneous Outstanding Shares99,150,000Free Float98,027,000Market Cap$302.41 million OptionableOptionable Beta0.47 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:XFOR) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.